Subsequently, our study established that two intratumoral doses of IL-15 complexes in combination with the checkpoint inhibitor against PD-1 can convert the resistant EO771 luminal B TME into one more susceptible to complete immune control, as observed by a dramatic reduction in tumor size and metastatic centers, and 90% tumor clearance in mice without recurrence. This evidence concerns the gene IL15 and neoplasm.